HUTCHMED (China)
HUTCHMED China Ltd is a Chinese commercial-stage biopharmaceutical company discovering and developing targeted therapies and immunotherapies for cancer and immunological diseases. The company researches, manufactures, and markets targeted small molecule oncology drugs including fruquintinib, surufatinib, and savolitinib, alongside prescription chemical pharmaceuticals in China. Main revenue drivers consist of commercial drug sales of proprietary oncology therapeutics, milestone payments from global biopharmaceutical partners, and pharmaceutical distribution revenues. HUTCHMED serves oncologists, medical research hospitals, and cancer patients in China, North America, and Europe. The company holds an established market position as a premier biopharmaceutical innovator originating from China. Headquartered in Hong Kong and Shanghai, China, it is listed on the AIM market, Nasdaq, and Hong Kong Stock Exchange.
2 of the funds FundTelligence covers report a position in HUTCHMED (China).
- Legal name
- HUTCHMED (China) Ltd
- Sector
- Health Care
- Country
- China
- Funds holding it
- 2
Funds holding HUTCHMED (China)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.01 % (full portfolio disclosed, October 2026)